Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial
暂无分享，去创建一个
J. Bruix | P. Galle | R. Finn | O. Yokosuka | G. Bodoky | G. Meinhardt | Yi‐Hsiang Huang | A. Granito | O. Rosmorduc | R. Gérolami | P. Merle | Weijing Sun | M. Leberre | M. Pracht | A. Baumhauer | Charissa Y. Chang | W. Sun | C. Caparello | R. Cabrera | C. Chang | P. Galle | R. Finn | G. Meinhardt | Yh-Hsiung Huang | W. Sun